Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Shareholder Meeting (November 2022)
23 slides from Paradigm Biopharmaceuticals's shareholder meeting presentation, Nov 29, 2022
Slide 1: 2022 Annual General Meeting
ASX RELEASE 29th November 2022 2022 Annual General Meeting For personal use only Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a late- stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to provide a copy of the Chairm
Slide 2: 2022 Annual General Meeting
For personal use only 2 0 2 2 A N N U A L G E N E R A L M E E T I N G
Slide 3: MD & Business Update
For personal use only Paradigm Biopharma Nov 2022 2 MD & Business Update Paul Rennie, Managing Director
Slide 4: Disclaimer
Paradigm Biopharma Nov 2022 3 Disclaimer For personal use only This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively,
Slide 5: Executive Team
For personal use only Paradigm Biopharma Nov 2022 4 PAUL DR. DONNA RENNIE SKERRETT Founder & Chief Medical Officer Chairman DR RAVI JUSTIN Executive Team KRISHNAN Chief Scientific Officer CAHILL Chief Financial Officer
Slide 6: Key Milestones Achieved FY22
Paradigm Biopharma Nov 2022 5 Osteoarthritis (OA) For personal use only • IND open for phase 3 clinical trial and Fast Track Designation granted by US FDA • Actively screening and enrolling participants in US, AU, UK • Globally harmonised clinical program will support: registration in multiple juris
Slide 7: Osteoarthritis
For personal use only Paradigm Biopharma 02/12/21 Nov 2022 66 Osteoarthritis OA
Slide 8: Osteoarthritis - Global Phase 3 Achievements
Paradigm Biopharma 02/12/21 Nov 2022 77 Osteoarthritis - Global Phase 3 Achievements PARA_OA_002 Global Progress For personal use only Harmonised clinical protocol to achieve simultaneous registration in key jurisdictions United States • Fast Track Designation • 50+ sites activated • Enrolling part
Slide 9: Key Objectives FY23: Lead Program Osteoarthritis
For personal use only Paradigm Biopharma 02/12/21 Nov 2022 88 KEY OBJECTIVES FY23 Data Safety Monitoring Board Review (DSMB) • Formal review by the DSMB for the PARA_OA_002 trial in December • Review and evaluation of the accumulated PARA_OA_002 study data PARA_OA_002 Stage 1 • 100% recruitment of s
Slide 10: Exploring the Potential of PPS as a DMOAD
Paradigm Biopharma 02/12/21 Nov 2022 99 EXPLORING THE POTENTIAL OF PPS AS A For personal use only DISEASE MODIFYING OA DRUG (DMOAD) PARA_OA_008 • Global market research detailed US$6000+ achievable for Zilosul® if DMOAD label achieved • Outstanding top-line results reported at day 56: • iPPS impacte
Slide 11: Mucopolysaccharidosis
For personal use only Paradigm Biopharma Nov 2022 1010 02/12/21 Mucopolysaccharidosis MPS
Slide 12: Mucopolysaccharidosis (MPS)
Paradigm Biopharma Nov 2022 11 Mucopolysaccharidosis (MPS) For personal use only MPS I - Australia Phase 2 asset in rare disease associated with inflammation & ongoing musculoskeletal pain: iPPS has FDA & EMA orphan designation for MPS • Open-label trial SC dosing subjects weekly for 12 weeks, then
Slide 13: Key Objectives FY23: Mucopolysaccharidosis
For personal use only Paradigm Biopharma Nov 2022 1212 02/12/21 KEY OBJECTIVES FY23 MPS-I • Data for the phase 2 study to be presented by Dr Bratkovic at ICLD 2023 and will cover information on pain, function, urinary GAGs, and change in biomarkers Mucopolysaccharidosis • Preparation for completion
Slide 14: For personal use only
For personal use only Paradigm Biopharma Nov 2022 1313 02/12/21 Company UPDATE
Slide 15: Exclusive supply and extensive IP protection
Paradigm Biopharma Nov 2022 14 14 Exclusive For personal use only Complex supply molecule Extensive Alphavirus Heart Failure ? Market Protection Arthroplasty Severe OA Pain Allergic ARDS Rhinitis • Multiple method of use patents, continually refined and expanded with additional PPS universe of MPS P
Slide 16: Business Development
For personal use only Paradigm Biopharma Nov 2022 1515 02/12/21 Plexus Ventures • Leading global business development firm serving the pharmaceutical industry for over 30 years Business • Plexus Ventures has a long track record of deal successes for or with many of the pharmaceutical industry's larg
Slide 17: Global Presence
Paradigm Biopharma Nov 2022 1616 02/12/21 Global and AU Conference Presentations past 12-months: For personal use only JP Morgan Healthcare Conference, Evercore ISI HealthCONx, Truist Life Sciences Conference, Goldman Sachs SMID Cap Conference, BIO Europe and International Partnering Conferences, Be
Slide 18: FY23 Key Milestones
For personal use only Paradigm Biopharma Nov 2022 1717 02/12/21 1. Secure funding to advance the development of Paradigm’s programs. 2. PARA_OA_002 Stage 1, 100% recruitment. FY23 3. OA manuscript following day 56 PARA_OA_008 readout, detailing biomarker and clinical outcomes completed for peer revi
Slide 19: Expected News Flow
For personal use only Paradigm Biopharma Nov 2022 1818 02/12/21 PARA_OA_006 extension study commencement Q4 CY2022 Expected News FY22 tax rebate of $7.4m Q4 CY2022 Flow • PARA_OA_002 update – First data safety monitoring board review Q4 CY2022 • MPS-VI phase 2 clinical trial – 100% recruitment Q
Slide 20: Appendix
For personal use only Paradigm Biopharma 25/01/22 19 Appendix
Slide 21: Corporate Snapshot and Top Holders
Paradigm Biopharma Nov 2022 20 Key Financial Details Top Holders For personal use only Ticker Symbol ASX:PAR Rank Name Units # Units % Trading Range (12mth) A$0.855 – $2.33 1 CITICORP NOMINEES PTY 22,318,994 7.83 LIMITED Share Price (25.11.22) ~A$ 1.465 HSBC CUSTODY NOMINEES 2 (AUSTRALIA) LIMIT
Slide 22: Share price and news events
Paradigm Biopharma Nov 2022 21 03 Nov 2021 $2.70 PAR cleared for phase 3 trial 9m For personal use only by US FDA 22 Nov 2021 CEO Paul Rennie to 11 Aug 2022 03 Aug 2021 transition to Non-Exec Trading Halt $2.50 PAR reports IND application Chairman 8m update (further clarification on one question) 16
Slide 23: For more information
For personal use only Paradigm Biopharma 25/01/22 22 For more information please visit: paradigmbiopharma.com or email any queries to investorrelations@paradigmbiopharma.com
Paradigm Biopharmaceuticals — Shareholder Meeting (November 2022) on 6ix